3Zhou H, Kim YS, Peletier A, et al. Effects of the EGFR/ HER2 kinase inhibitor GW572016 on EGFR- and HER2- overexpressing breast cancer cell line proliferation, radiosensitization, and resistance [ J ]. Int J Radiat Oncol Biol Phys, 2004,58 ( 2 ) : 344.
4Chu I, Blackwe11 K, Chen S, et al. The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen- resistant breast cancer [ J ]. Cancer Res, 2005 , 65 (1):18.
5Ito Y, Tokudome N, Sugihara T, et al. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer [ J ] ? Breast Cancer, 2007,14 ( 2 ) : 156.
6Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue [ J ]. Clin Breast Cancer, 2007,7 ( 7 ) :543.
7Mani S, Mcdaid H, Hamilton A,et al. Phase I clinical and pharmacokinetic study of BMS-247550 a novel derivative of epothilone B,in solid tumors [ J]. Clinical Cancer Res, 2004,10(2) :1289.
8Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine [ J ]. J Clin Oncol, 2007,25 ( 23 ) : 3407.
9Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte [ J ]. J Clin Oncol, 2005,23(18) :4117.
10Czuczman Ms. Immune chemotherapy in indolent non Hodgkin' s lymphoma [ J ]. Clinical Oncol, 2006, 29 ( 2 supply 6) :S11.
